CMMB

Chemomab Therapeutics Ltd. [CMMB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CMMB Stock Summary

Top 10 Correlated ETFs

CMMB


Top 10 Correlated Stocks

CMMB


In the News

01:32 28 Mar 2024 CMMB

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

11:20 28 Mar 2024 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

07:00 28 Mar 2024 CMMB

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

11:43 28 Mar 2024 CMMB

Chemomab (CMMB) Stock Gains 30% on FDA Clearance

There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.

08:25 28 Mar 2024 CMMB

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.

12:00 28 Mar 2024 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.

07:00 28 Mar 2024 CMMB

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.

02:40 28 Mar 2024 CMMB

Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.

07:00 28 Mar 2024 CMMB

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

07:00 28 Mar 2024 CMMB

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.

CMMB Financial details

Company Rating
Neutral
Market Cap
10.49M
Income
-24.24M
Revenue
0
Book val./share
1.31
Cash/share
1.53
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.18
Forward P/E
-7.5
PEG
0.14
P/S
-
P/B
0.27
P/C
0.49
P/FCF
-0.26
Quick Ratio
4.05
Current Ratio
4.06
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-0.1
EPS next Q
-0.02
EPS this Y
-15.23%
EPS next Y
-95.28%
EPS next 5Y
-97.17%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.59%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.1%
Inst Trans
1%
ROA
-115%
ROE
-102%
ROC
-1.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
13.62M
Shs Float
10.77M
-
-
-
-
Target Price
-
52W Range
0.42-1.89
52W High
-
52W Low
-
RSI
54
Rel Volume
-
Avg Volume
245.83K
Volume
1.07K
Perf Week
-4.93%
Perf Month
22.97%
Perf Quarter
-14.76%
Perf Half Y
-17.57%
-
-
-
-
Beta
-0.098
-
-
Volatility
0.02%, 0.06%
Prev Close
-2.58%
Price
0.7501
Change
0.91%

CMMB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-15.75-0.54-1.21-2.43-2.06
Operating cash flow per share
-9.56-0.48-1.19-1.790
Free cash flow per share
-9.61-0.48-1.22-1.80
Cash per share
10.21.065.93.511.69
Book value per share
8.660.985.933.181.45
Tangible book value per share
8.660.985.933.181.45
Share holders equity per share
8.660.985.933.181.45
Interest debt per share
0.650.040.040.050.01
Market cap
38.58M304.56M71.58M36.41M5.99M
Enterprise value
22.12M293.31M57.23M23.11M-2.98M
P/E ratio
-1.42-51.36-5.7-1.32-0.25
Price to sales ratio
00000
POCF ratio
-2.34-58.1-5.78-1.790
PFCF ratio
-2.33-57.68-5.67-1.780
P/B Ratio
2.5928.191.161.010.35
PTB ratio
2.5928.191.161.010.35
EV to sales
00000
Enterprise value over EBITDA
-1.15-49.31-4.63-0.810.12
EV to operating cash flow
-1.34-55.95-4.63-1.130
EV to free cash flow
-1.34-55.55-4.54-1.130
Earnings yield
-0.7-0.02-0.18-0.76-4.03
Free cash flow yield
-0.43-0.02-0.18-0.560
Debt to equity
0.070.040.010.010
Debt to assets
0.060.030.0100
Net debt to EBITDA
0.851.891.160.470.35
Current ratio
4.42923.666.184.32
Interest coverage
-2.17K-995.33-111.64-80.830
Income quality
0.610.880.990.740
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.0200
Capex to revenue
00000
Capex to depreciation
-0.34-1.58-7.03-1.170
Stock based compensation to revenue
00000
Graham number
55.383.4512.713.198.18
ROIC
-1.17-0.51-0.2-0.76-1.46
Return on tangible assets
-1.37-0.48-0.2-0.64-1.09
Graham Net
7.670.893.442.931.32
Working capital
14.09M10.52M60.04M34.99M16.06M
Tangible asset value
14.91M10.8M61.47M36.22M17M
Net current asset value
13.37M10.17M59.8M34.9M15.74M
Invested capital
0.070.040.010.010
Average receivables
318K355K800.5K993K748K
Average payables
437.5K484K714.5K1.51M1.1M
Average inventory
-271-328.77K-24.08M-23.75M0
Days sales outstanding
00000
Days payables outstanding
1.14K424.3214.33K10.66K0
Days of inventory on hand
-0.7-3K-509.6K00
Receivables turnover
00000
Payables turnover
0.320.860.030.030
Inventory turnover
-518.45-0.12000
ROE
-1.82-0.55-0.2-0.76-1.42
Capex per share
-0.060-0.02-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.73-0.79-0.72-0.34-0.27
Operating cash flow per share
-0.51-0.65-0.68-0.430
Free cash flow per share
-0.51-0.65-0.68-0.430
Cash per share
3.542.962.41.811.53
Book value per share
3.222.531.981.531.31
Tangible book value per share
3.222.531.981.531.31
Share holders equity per share
3.222.531.981.531.31
Interest debt per share
0.05-1.590.010.010.01
Market cap
36.05M17.57M14.63M10.58M6.64M
Enterprise value
22.74M-3.02M4.39M1.46M-2.34M
P/E ratio
-1.09-0.5-0.46-0.65-0.48
Price to sales ratio
00000
POCF ratio
-6.32-2.44-1.95-2.060
PFCF ratio
-6.32-2.44-1.95-2.060
P/B Ratio
10.630.670.590.39
PTB ratio
10.630.670.590.39
EV to sales
00000
Enterprise value over EBITDA
-2.640.33-0.54-0.340.6
EV to operating cash flow
-3.990.42-0.59-0.290
EV to free cash flow
-3.990.42-0.59-0.290
Earnings yield
-0.23-0.5-0.54-0.38-0.52
Free cash flow yield
-0.16-0.41-0.51-0.480
Debt to equity
0.010.010.010.010
Debt to assets
00.01000
Net debt to EBITDA
1.542.281.252.12.31
Current ratio
6.184.834.064.164.32
Interest coverage
-22.740.51000
Income quality
0.690.820.941.260
Dividend Yield
0.030000
Payout ratio
-0.140000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.07-0.06-0.1300
Stock based compensation to revenue
00000
Graham number
7.296.715.673.442.79
ROIC
-0.24-0.32-0.37-0.24-0.22
Return on tangible assets
-0.19-0.25-0.28-0.17-0.16
Graham Net
2.961.81.851.421.19
Working capital
34.99M26.78M20.88M17M16.06M
Tangible asset value
36.22M27.95M21.99M18.04M17M
Net current asset value
34.9M26.72M20.85M16.99M15.74M
Invested capital
0.010.010.010.010
Average receivables
1.36M727K1.02M981.99K979.5K
Average payables
1.47M1.95M2.28M1.54M623.5K
Average inventory
-18.99M-6.47M-6.43M36.44K0
Days sales outstanding
00000
Days payables outstanding
10.88K22.0513.35K3.47K0
Days of inventory on hand
0-128.66414.6900
Receivables turnover
00000
Payables turnover
0.014.080.010.030
Inventory turnover
0-0.70.2200
ROE
-0.23-0.31-0.36-0.23-0.2
Capex per share
00000

CMMB Frequently Asked Questions

What is Chemomab Therapeutics Ltd. stock symbol ?

Chemomab Therapeutics Ltd. is a IL stock and trading under the symbol CMMB

What is Chemomab Therapeutics Ltd. stock quote today ?

Chemomab Therapeutics Ltd. stock price is $0.7501 today.

Is Chemomab Therapeutics Ltd. stock public?

Yes, Chemomab Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap